CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.
Himelstein A, Qin R, Novotny P, Seisler D, Khatcheressian J, Roberts J, Grubbs S, O'Connor T, Weckstein D, Loprinzi C, Shapiro C. CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal Of Clinical Oncology 2015, 33: 9501-9501. DOI: 10.1200/jco.2015.33.15_suppl.9501.Peer-Reviewed Original ResearchRandomized phase III studyPhase III studyInterval dosingStandard dosingIII studyZoledronic acidMetastatic cancerDosingCancer